Jul 19, 2024, 22:55
What after Osimertinib failure?
Abhishek Pathak, Professor at the Indian Army, shared a post on X:
“What after Osimertinib failure?
Results from MARIPOSA 2.
PFS advantage at best. Did Lazertinib really help?”
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared this post, adding:
“Chemo plus ami will be the new standard, approved by FDA/EMA.
No lazertinib required…”
Sources: Abhishek Pathak/X and Antonio Passaro/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59
Nov 13, 2024, 10:54